Meaning-Centered Psychotherapy in Advanced Cancer

This study has been completed.

First Received: August 14, 2003 Last Updated: August 16, 2006 History of Changes

Sponsor:	National Center for Complementary and Alternative Medicine (NCCAM)
Information provided by:	National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier:	NCT00067288

Purpose

We have developed an 8-week Meaning-Centered Group Psychotherapy designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose despite the limitations of their cancer illness. This project's overall aim is to explore the feasibility and efficacy of this new and unique psychotherapy intervention for advanced cancer patients in enhancing psychological and spiritual well-being and quality of life by comparing it with a standard supportive group psychotherapy.

Condition	Intervention	Phase
Lymphoma, Non-Hodgkin Neoplasms	Behavioral: Meaning-Centered Group Psychotherapy Behavioral: Standard Supportive Group Psychotherapy	Phase II

Study Type:	Interventional
Study Design:	Educational/Counseling/Training, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title:	Meaning-Centered Psychotherapy in Advanced Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lymphoma

U.S. FDA Resources

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment:	118
Study Start Date:	May 2002
Estimated Study Completion Date:	March 2006

Detailed Description:

As per Brief Summary

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

21 years of age or older;
English speaking;
Stage III or IV solid-tumor or Non-Hodgkin's Lymphoma;
Receiving ambulatory care at Memorial Sloan-Kettering Cancer Center in New York City;

Exclusion Criteria:

Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in a group-format intervention;
Presence of cognitive impairment disorder, such as delirium or dementia that is sufficient, in the investigator's opinion, to preclude meaningful participation and/or informed consent;
Karnofsky Performance Rating Scale below 50 or physical limitations or illness severity sufficient to preclude participation in outpatient group psychotherapy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067288

Locations

United States, New York
Memorial Sloan-Kettering Institute for Cancer Research
New York, New York, United States, 10021

Sponsors and Collaborators

National Center for Complementary and Alternative Medicine (NCCAM)

Investigators

Principal Investigator:	William Breitbart, MD	Memorial Sloan-Kettering Cancer Center
Investigator:	Christopher Gibson, PhD	Project Coordinator Memorial Sloan-Kettering Cancer Center

More Information

No publications provided

Study ID Numbers:	R21 AT001031-01, Breitbart
Study First Received:	August 14, 2003
Last Updated:	August 16, 2006
ClinicalTrials.gov Identifier:	NCT00067288 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):

Stage 3 cancer;
Stage 4 cancer;
solid tumor cancer;
Non-Hodgkin's Lymphoma;
solid tumors;

end-stage cancer;
group psychotherapy;
psychotherapy;
emotional support;
support groups

Additional relevant MeSH terms:

Lymphatic Diseases
Neoplasms
Immunoproliferative Disorders
Neoplasms by Histologic Type

Immune System Diseases
Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin
Lymphoma

ClinicalTrials.gov processed this record on November 27, 2009